DYADIC INTERNATIONAL INC Deferred Tax Assets, in Process Research and Development
DYADIC INTERNATIONAL INC (DYAI) had Deferred Tax Assets, in Process Research and Development of $1.56 million as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment · last filed 2026-08-12
- 2026-06-30: Deferred Tax Assets, in Process Research and Development $1.56M.
- 2026-03-31: Deferred Tax Assets, in Process Research and Development $1.06M.
- 2025-12-31: Deferred Tax Assets, in Process Research and Development $1.31M.
- 2025-09-30: Deferred Tax Assets, in Process Research and Development $1.32M.
| Period end | Deferred Tax Assets, in Process Research and Development |
|---|---|
| 2026-06-30 | $1.56M 10-Q · filed 2026-08-12 |
| 2026-03-31 | $1.06M 10-Q · filed 2026-05-13 |
| 2025-12-31 | $1.31M 10-K · filed 2026-03-25 |
| 2025-09-30 | $1.32M 10-Q · filed 2025-11-12 |
| 2025-06-30 | $1.83M 10-Q · filed 2025-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |